Jesús Jiménez-López

Exploring strategic options for Europe 🇪🇺 with your hashtag #orphandrug? Reach out to Eva Cruz de Castro to meet in the sunny #SanDiego 🇺🇸 at the upcoming Biotechnology Innovation Organization International Convention to explore a partnership with Avanzanite Bioscience. Avanzanite acquires, licenses or distributes market-ready medicines for #rarediseases and commercialises them everywhere in Europe, even where nobody else will – so that NO ONE'S LEFT BEHIND. If that resonates, email: [email protected]. You should particularly meet Eva Cruz de Castro if you face challenges in Europe 🇪🇺. Perhaps, there are very few patients that could use your medicine. Or the market access issues are overwhelming. Or simply, you only have a bandwith to go to to 2–3 countries at launch. Whatever is the trouble, we love challenges. Our confidence is not superficial. We have an unrivalled track record in market access and market development. And we will make sure that all back-end operations are running smoothly - distribution, pharmacovigilance, medical information, quality, compliance etc. And when needed, we will step in a bit earlier to tie things up together - with regulatory submission, some outstanding CMC work, patent prosecution etc.

7

Ayahuasca is naturally derived from two plants: the Banisteriopsis caapi vine and the hallucinogenic plant, Psychotria viridis, also known as Chacruna. It is a psychedelic that contains DMT. In contrast, ibogaine, one alkaloid derived from the iboga plant, does not contain DMT. At Beond, we use ibogaine in its hydrochloric form; it is still a plant medicine but it is purified in a lab and measured for potency. Both ayahuasca and iboga are seen as sacred plants. Ayahuasca is typically used more ritualistically in group settings. Ibogaine treatments at Beond, however, are individualized; we usually treat only one or two people at a time in a more clinical setting. The environment is controlled with low lights, noise-canceling headphones, and eye masks, and while some ritual elements can be included upon request, medical equipment is always present to monitor heart patterns because ibogaine affects the heart, making medical supervision essential. The psychedelic effects of the two substances differ significantly. Ayahuasca, containing DMT, induces experiences characterized by out-of-the-mind sensations and ego dissolution. Because ibogaine does not contain DMT, the rational mind remains more present. The insights gained during the ibogaine experience are drawn from personal memories and life experiences, helping to unravel and explore long-held thought patterns. This offers an opportunity to observe the workings of the mind, gain new perspectives on past events, and facilitate healing. While ayahuasca often provides profound visions that impart universal lessons, ibogaine typically explores more personal realms, such as family lineage and deep-seated memories. It reveals layers of thoughts, fears, and experiences, allowing individuals to objectively witness their life's narratives. What has your experience been with either of these plant medicines? What other aspects do you feel differ? 

27

1 comentario

Our colleague Juan Carlos Triviño, PhD, BioInformatic Expert in Sistemas Genómicos | member of SYNLAB, is leading session #3: "Beyond DNA: Regulatory-region analysis and its possible impact on clinical diagnosis", of our symposium: "NEW TECHNOLOGIES AND APPROACHES IN CLINICAL GENOMICS" at ESHG2024. Regulatory-region analysis is not just a tool, but a key to unlocking a comprehensive understanding of genetic diseases. By including these regions in genetic testing, we can significantly enhance diagnostic accuracy, inform personalized treatment strategies, and provide invaluable insights for genetic counselling. As sequencing technologies and bioinformatics tools continue to advance, the ability to detect and interpret regulatory mutations will improve, leading to better clinical outcomes and more precise medical interventions. More info: [email protected] We look forward to seeing you at our booth #570 #ESHG2024 #Genetic #SistemasGenomicos

45

🔬 Exciting news from the biotech sector in #Catalonia! 🌍According to AseBio - Asociación Española de Bioempresas's 2023 Report "25 years of biotechnology," Catalonia leads the way, hosting nearly 25% of the total number of biotechnology companies in the country. 👩‍🔬This reflects the region's strong position as a hub for health and #biotechnology businesses, contributing to Europe's thriving biotech landscape. 🏥 With 242 companies, Catalonia's biotech sector accounts for over a third of Spain's total business revenue. This impressive growth underscores the region's significance in driving innovation and scientific production in biotechnology. 🗣Rocio Arroyo, President of AseBio - Asociación Española de Bioempresas, has stated: "Spain is a powerhouse in scientific production in biotechnology, ranking 9th in the world." 💹 As the biotech sector continues to flourish, Catalonia is set for further growth and contribution to the industry! Read the news ⤵ https://lnkd.in/dfKH2stE #Biotechnology #Catalonia #Spain #Business #Innovation #AseBio #Healthcare

14

IDIBELL SCTs AT THE CataloniaBioHT CONNECTION DAY. We are very excited to participate in the CataloniaBio & HealthTech Connection Day to present our IDIBELL Scientific and Technical Services to the Pharma sector, with the motto: “Facing problems? We have solutions. Reach out!”. Particularly to showcase our new equipment: Simoa (Quanterix) ultra-sensitive biomarker detector which allows for picogram-level detection as opposed to nanograms (in blood samples instead of cerebrospinal fluid for example) and CosMx (Nanostring, presumably, still in a public tender process), enabling the quantification and histological localization of thousands of transcriptomic and proteomic markers at single-cell resolution. #CataloniaBioHT #IDIBELL #SCT #CosMx #Simoa #Nanostring #Quanterix #Neurosciences #Cancer #CERCA #CERCAGinys

25

2 comentarios